Clinical Trial

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Name: Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma — clinical trial record (NCT07622706)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Trial Details

NCT Number	NCT07622706
Lead Sponsor	Peking University Cancer Hospital & Institute
Conditions	NSCLC, EGFR Positive Non-small Cell Lung Cancer, Neoadjuvant Therapy
Enrollment	60 participants
Start Date	2026-05-30
Primary Completion	2028-05-30 (estimated)
Study Completion	2029-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-03